Status:
COMPLETED
Is the Concentration of Anti-Muellerian Hormon (AMH) Depending on the Menstrual Cycle?
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Roche Diagnostic Ltd.
Conditions:
Ovarian Failure
Eligibility:
FEMALE
18-40 years
Brief Summary
The developement of a new, stable measurement of the Antimuellerian Hormon (AMH) together with Roche Diagnostics International (Rotkreuz, CH) shall enable an automized and timely measurement of AMH va...
Detailed Description
An important requirement for the use of the new measurement to determine the AMH concentration is the stability of the AMH level over the menstrual cycle. So far the unbiased AMH concentration is the ...
Eligibility Criteria
Inclusion
- Regular natural menstrual cycle between 24 and 32 days
- Body Mass Index (BMI) between 19 and 26 kg/m2
- Negative serum titer for HIV, Hepatitis B and Hepatitis C
- Non-smoker
- Willingness to visit the clinic every second day of two non-consecutive menstrual cycles.
Exclusion
- Intake of hormonal medication like contraceptives
- Pregnancy/breast feeding
- Known infertility
- Known former or actual hormonal disorder
- Polycystic ovarial syndrom (PCOS)
- Participation on another clinical trial during the last 3 months.
Key Trial Info
Start Date :
November 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 13 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03398603
Start Date
November 1 2016
End Date
October 13 2019
Last Update
January 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinik für Gyn. Endokrinologie und Reproduktionsmedizin der Frauenklinik des Universitätsspitals
Basel, Switzerland, 4031